A dual-prodrug nanoparticle based on chitosan oligosaccharide for enhanced tumor-targeted drug delivery

Xia Chen; David H. Bremner; Yuhan Ye; Jiadong Lou; Shiwei Niu; Li-Min Zhu

doi:10.1016/j.colsurfa.2021.126512

A dual-prodrug nanoparticle based on chitosan oligosaccharide for enhanced tumor-targeted drug delivery

Xia Chen
, David H. Bremner
, Yuhan Ye
, Jiadong Lou
, Shiwei Niu^*
, Li-Min Zhu^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

The premature leakage of chemotherapeutics during delivery impedes drugs from entering tumor cells, which produces considerable side effects in normal organs. Herein, we describe a hydrophobic-hydrophilic balanced self-assembled prodrug nanoparticle (HA-DOX@HA-CSO-g-OA), formed via a facile synthesis based on chitosan oligosaccharide to reduce the non-targeting risk of premature leakage of chemotherapeutics during their delivery. The HA-DOX@HA-CSO-g-OA have a suitable size (~186 nm) with a doxorubicin (DOX) loading of 9.88% and an oleanolic acid (OA) loading efficiency of 27.34%. The release of DOX or OA is pH-dependent and responds particularly well to the acidic tumor microenvironment. In vitro antitumor activity studies revealed that HA-DOX@HA-CSO-g-OA had enhanced performance in promoting tumor apoptosis and displayed significant anticancer effects compared to mono-delivery. In vitro cell studies showed that HA-functionalized nanoparticles could enhance the cellular uptake in tumor cells. Therefore, HA-DOX@HA-CSO-g-OA is a promising vehicle for CD44-targeted co-delivery of cancer chemotherapy, which deserves further evaluation.

Original language	English
Article number	126512
Number of pages	33
Journal	Colloids and Surfaces A: Physicochemical and Engineering Aspects
Volume	619
Early online date	26 Mar 2021
DOIs	https://doi.org/10.1016/j.colsurfa.2021.126512
Publication status	Published - 20 Jun 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Chitosan oligosaccharide
Prodrug
Controlled release
Targeted tumor
Chemotherapy

Access to Document

10.1016/j.colsurfa.2021.126512

Cite this

@article{59ccbcb1bade4cad8b16cf482af1fb84,

title = "A dual-prodrug nanoparticle based on chitosan oligosaccharide for enhanced tumor-targeted drug delivery",

abstract = "The premature leakage of chemotherapeutics during delivery impedes drugs from entering tumor cells, which produces considerable side effects in normal organs. Herein, we describe a hydrophobic-hydrophilic balanced self-assembled prodrug nanoparticle (HA-DOX@HA-CSO-g-OA), formed via a facile synthesis based on chitosan oligosaccharide to reduce the non-targeting risk of premature leakage of chemotherapeutics during their delivery. The HA-DOX@HA-CSO-g-OA have a suitable size (\textasciitilde{}186 nm) with a doxorubicin (DOX) loading of 9.88\% and an oleanolic acid (OA) loading efficiency of 27.34\%. The release of DOX or OA is pH-dependent and responds particularly well to the acidic tumor microenvironment. In vitro antitumor activity studies revealed that HA-DOX@HA-CSO-g-OA had enhanced performance in promoting tumor apoptosis and displayed significant anticancer effects compared to mono-delivery. In vitro cell studies showed that HA-functionalized nanoparticles could enhance the cellular uptake in tumor cells. Therefore, HA-DOX@HA-CSO-g-OA is a promising vehicle for CD44-targeted co-delivery of cancer chemotherapy, which deserves further evaluation.",

author = "Xia Chen and Bremner, \{David H.\} and Yuhan Ye and Jiadong Lou and Shiwei Niu and Li-Min Zhu",

note = "Funding Information: This research was financially supported by grant 16410723700 from the Science and Technology Commission of Shanghai Municipality , and the National Natural Science Foundation of China ( 81460647 ). Publisher Copyright: {\textcopyright} 2021 Elsevier B.V. ",

year = "2021",

month = jun,

day = "20",

doi = "10.1016/j.colsurfa.2021.126512",

language = "English",

volume = "619",

journal = "Colloids and Surfaces A: Physicochemical and Engineering Aspects",

issn = "0927-7757",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - A dual-prodrug nanoparticle based on chitosan oligosaccharide for enhanced tumor-targeted drug delivery

AU - Chen, Xia

AU - Bremner, David H.

AU - Ye, Yuhan

AU - Lou, Jiadong

AU - Niu, Shiwei

AU - Zhu, Li-Min

N1 - Funding Information: This research was financially supported by grant 16410723700 from the Science and Technology Commission of Shanghai Municipality , and the National Natural Science Foundation of China ( 81460647 ). Publisher Copyright: © 2021 Elsevier B.V.

PY - 2021/6/20

Y1 - 2021/6/20

N2 - The premature leakage of chemotherapeutics during delivery impedes drugs from entering tumor cells, which produces considerable side effects in normal organs. Herein, we describe a hydrophobic-hydrophilic balanced self-assembled prodrug nanoparticle (HA-DOX@HA-CSO-g-OA), formed via a facile synthesis based on chitosan oligosaccharide to reduce the non-targeting risk of premature leakage of chemotherapeutics during their delivery. The HA-DOX@HA-CSO-g-OA have a suitable size (~186 nm) with a doxorubicin (DOX) loading of 9.88% and an oleanolic acid (OA) loading efficiency of 27.34%. The release of DOX or OA is pH-dependent and responds particularly well to the acidic tumor microenvironment. In vitro antitumor activity studies revealed that HA-DOX@HA-CSO-g-OA had enhanced performance in promoting tumor apoptosis and displayed significant anticancer effects compared to mono-delivery. In vitro cell studies showed that HA-functionalized nanoparticles could enhance the cellular uptake in tumor cells. Therefore, HA-DOX@HA-CSO-g-OA is a promising vehicle for CD44-targeted co-delivery of cancer chemotherapy, which deserves further evaluation.

AB - The premature leakage of chemotherapeutics during delivery impedes drugs from entering tumor cells, which produces considerable side effects in normal organs. Herein, we describe a hydrophobic-hydrophilic balanced self-assembled prodrug nanoparticle (HA-DOX@HA-CSO-g-OA), formed via a facile synthesis based on chitosan oligosaccharide to reduce the non-targeting risk of premature leakage of chemotherapeutics during their delivery. The HA-DOX@HA-CSO-g-OA have a suitable size (~186 nm) with a doxorubicin (DOX) loading of 9.88% and an oleanolic acid (OA) loading efficiency of 27.34%. The release of DOX or OA is pH-dependent and responds particularly well to the acidic tumor microenvironment. In vitro antitumor activity studies revealed that HA-DOX@HA-CSO-g-OA had enhanced performance in promoting tumor apoptosis and displayed significant anticancer effects compared to mono-delivery. In vitro cell studies showed that HA-functionalized nanoparticles could enhance the cellular uptake in tumor cells. Therefore, HA-DOX@HA-CSO-g-OA is a promising vehicle for CD44-targeted co-delivery of cancer chemotherapy, which deserves further evaluation.

U2 - 10.1016/j.colsurfa.2021.126512

DO - 10.1016/j.colsurfa.2021.126512

M3 - Article

SN - 0927-7757

VL - 619

JO - Colloids and Surfaces A: Physicochemical and Engineering Aspects

JF - Colloids and Surfaces A: Physicochemical and Engineering Aspects

M1 - 126512

ER -

A dual-prodrug nanoparticle based on chitosan oligosaccharide for enhanced tumor-targeted drug delivery

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this